Streetbeat News

Price Targets

NTAP

Evercore ISI Group has maintained an In-Line rating on NetApp (NASDAQ:NTAP) and raised the price target from $120 to $130.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 2:03 pm

KRYS

Evercore ISI Group maintains an Outperform rating on Krystal Biotech (NASDAQ:KRYS) and raises the price target from $201 to $206.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 2:01 pm

LTRN

Zacks Small Cap Research has given Lantern Pharma (LTRN) a price valuation of $26. This valuation reflects a positive outlook for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 2:01 pm

TASK

TaskUs (NASDAQ:TASK) has received diverse analyst ratings over the past three months, with a mix of bullish, somewhat bullish, indifferent, and bearish perspectives. The average 12-month price target has increased by 9.29% to $16.83. Recent analyst actions include multiple rating raises and price target adjustments, reflecting a positive shift in sentiment.

Portfolio Pulse from Benzinga Insights

August 12, 2024 | 2:01 pm

PCAR

PACCAR (NASDAQ:PCAR) has been analyzed by six analysts, revealing a range of sentiments from bullish to bearish. Recent ratings show a shift towards a more neutral stance, with price targets being lowered. The average 12-month price target is now $110.17, down from $119.60. Key analysts from Citigroup, Deutsche Bank, JP Morgan, and Truist Securities have all lowered their price targets and ratings for PACCAR.

Portfolio Pulse from Benzinga Insights

August 12, 2024 | 2:00 pm

IOVA

Iovance Biotherapeutics (NASDAQ: IOVA) has received mixed analyst ratings over the past three months, with a majority being bullish. The average 12-month price target has decreased to $27.57 from $29.14. Analysts have maintained or lowered their ratings, reflecting varied sentiments about the company's future performance.

Portfolio Pulse from Benzinga Insights

August 12, 2024 | 2:00 pm

MDT

Medtronic (NYSE:MDT) has received mixed analyst ratings over the past quarter, with a range of price targets and recommendations. The average 12-month price target is $88.67, with a high of $105.00 and a low of $76.00. Analysts have adjusted their ratings and price targets based on recent company performance and market conditions.

Portfolio Pulse from Benzinga Insights

August 12, 2024 | 2:00 pm

ARHS

Arhaus shares are trading lower after Stifel lowered its price target on the stock from $19.5 to $16.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 2:00 pm

EXPE

Over the past three months, 15 analysts have shared their evaluations of Expedia Group (NASDAQ:EXPE), revealing a range of outlooks from bullish to bearish. The average 12-month price target is $143.73, with a high of $180.00 and a low of $125.00. Recent analyst actions include both raises and lowers in price targets, reflecting mixed sentiments. Expedia's financial performance shows strong revenue growth and return on equity but challenges in net margin and return on assets.

Portfolio Pulse from Benzinga Insights

August 12, 2024 | 2:00 pm

OPRX

Analysts have provided mixed ratings for OptimizeRx (NASDAQ:OPRX) over the past quarter, with a recent average 12-month price target of $14.4, down 4% from the prior average. Key analysts have adjusted their ratings and price targets, reflecting changing market dynamics and company performance. OptimizeRx has shown a positive revenue trend with a 51.43% growth rate, but faces challenges with a net margin of -35.04%.

Portfolio Pulse from Benzinga Insights

August 12, 2024 | 2:00 pm